The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Non-small Cell Lung Cancer Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
The global Non-small Cell Lung Cancer Therapeutics market size is expected to reach US$ 14010 million by 2029, growing at a CAGR of 6.3% from 2023 to 2029. The market is mainly driven by the significant applications of Non-small Cell Lung Cancer Therapeutics in various end use industries. The expanding demands from the Hospital and Clinic, are propelling Non-small Cell Lung Cancer Therapeutics market. Alimta, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Iressa segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Non-small Cell Lung Cancer Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Non-small Cell Lung Cancer Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Non-small Cell Lung Cancer Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Non-small Cell Lung Cancer Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Non-small Cell Lung Cancer Therapeutics covered in this report include GlaxoSmithKline, Novartis, AstraZeneca, Roche, Bristol-Myers Squibb, Pfizer, Eli Lilly and Sanofi, etc.
The global Non-small Cell Lung Cancer Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GlaxoSmithKline
Novartis
AstraZeneca
Roche
Bristol-Myers Squibb
Pfizer
Eli Lilly
Sanofi
Global Non-small Cell Lung Cancer Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Non-small Cell Lung Cancer Therapeutics market, Segment by Type:
Alimta
Iressa
Avastin
Tarceva
Zykadia
Tagrisso
Xalkori
Cyramza
Opdivo
Alecensa
Global Non-small Cell Lung Cancer Therapeutics market, by Application
Hospital
Clinic
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Non-small Cell Lung Cancer Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Non-small Cell Lung Cancer Therapeutics market size is expected to reach US$ 14010 million by 2029, growing at a CAGR of 6.3% from 2023 to 2029. The market is mainly driven by the significant applications of Non-small Cell Lung Cancer Therapeutics in various end use industries. The expanding demands from the Hospital and Clinic, are propelling Non-small Cell Lung Cancer Therapeutics market. Alimta, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Iressa segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Non-small Cell Lung Cancer Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Non-small Cell Lung Cancer Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Non-small Cell Lung Cancer Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Non-small Cell Lung Cancer Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Non-small Cell Lung Cancer Therapeutics covered in this report include GlaxoSmithKline, Novartis, AstraZeneca, Roche, Bristol-Myers Squibb, Pfizer, Eli Lilly and Sanofi, etc.
The global Non-small Cell Lung Cancer Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GlaxoSmithKline
Novartis
AstraZeneca
Roche
Bristol-Myers Squibb
Pfizer
Eli Lilly
Sanofi
Global Non-small Cell Lung Cancer Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Non-small Cell Lung Cancer Therapeutics market, Segment by Type:
Alimta
Iressa
Avastin
Tarceva
Zykadia
Tagrisso
Xalkori
Cyramza
Opdivo
Alecensa
Global Non-small Cell Lung Cancer Therapeutics market, by Application
Hospital
Clinic
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Non-small Cell Lung Cancer Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Non-small Cell Lung Cancer Therapeutics
1.1 Non-small Cell Lung Cancer Therapeutics Market Overview
1.1.1 Non-small Cell Lung Cancer Therapeutics Product Scope
1.1.2 Non-small Cell Lung Cancer Therapeutics Market Status and Outlook
1.2 Global Non-small Cell Lung Cancer Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Non-small Cell Lung Cancer Therapeutics Market Size by Region (2018-2029)
1.4 Global Non-small Cell Lung Cancer Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Non-small Cell Lung Cancer Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Non-small Cell Lung Cancer Therapeutics Market Size (2018-2029)
1.6.1 North America Non-small Cell Lung Cancer Therapeutics Market Size (2018-2029)
1.6.2 Europe Non-small Cell Lung Cancer Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size (2018-2029)
1.6.4 Latin America Non-small Cell Lung Cancer Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size (2018-2029)
2 Non-small Cell Lung Cancer Therapeutics Market by Type
2.1 Introduction
2.1.1 Alimta
2.1.2 Iressa
2.1.3 Avastin
2.1.4 Tarceva
2.1.5 Zykadia
2.1.6 Tagrisso
2.1.7 Xalkori
2.1.8 Cyramza
2.1.9 Opdivo
2.1.10 Alecensa
2.2 Global Non-small Cell Lung Cancer Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Non-small Cell Lung Cancer Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Non-small Cell Lung Cancer Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Non-small Cell Lung Cancer Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Non-small Cell Lung Cancer Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Non-small Cell Lung Cancer Therapeutics Revenue Breakdown by Type (2018-2029)
3 Non-small Cell Lung Cancer Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.2 Global Non-small Cell Lung Cancer Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Non-small Cell Lung Cancer Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Non-small Cell Lung Cancer Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Non-small Cell Lung Cancer Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Non-small Cell Lung Cancer Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Non-small Cell Lung Cancer Therapeutics Revenue Breakdown by Application (2018-2029)
4 Non-small Cell Lung Cancer Therapeutics Competition Analysis by Players
4.1 Global Non-small Cell Lung Cancer Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Non-small Cell Lung Cancer Therapeutics as of 2022)
4.3 Date of Key Players Enter into Non-small Cell Lung Cancer Therapeutics Market
4.4 Global Top Players Non-small Cell Lung Cancer Therapeutics Headquarters and Area Served
4.5 Key Players Non-small Cell Lung Cancer Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Non-small Cell Lung Cancer Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 GlaxoSmithKline
5.1.1 GlaxoSmithKline Profile
5.1.2 GlaxoSmithKline Main Business
5.1.3 GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.1.4 GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 GlaxoSmithKline Recent Developments
5.2 Novartis
5.2.1 Novartis Profile
5.2.2 Novartis Main Business
5.2.3 Novartis Non-small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.2.4 Novartis Non-small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Novartis Recent Developments
5.3 AstraZeneca
5.3.1 AstraZeneca Profile
5.3.2 AstraZeneca Main Business
5.3.3 AstraZeneca Non-small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.3.4 AstraZeneca Non-small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Roche Recent Developments
5.4 Roche
5.4.1 Roche Profile
5.4.2 Roche Main Business
5.4.3 Roche Non-small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.4.4 Roche Non-small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Roche Recent Developments
5.5 Bristol-Myers Squibb
5.5.1 Bristol-Myers Squibb Profile
5.5.2 Bristol-Myers Squibb Main Business
5.5.3 Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.5.4 Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Bristol-Myers Squibb Recent Developments
5.6 Pfizer
5.6.1 Pfizer Profile
5.6.2 Pfizer Main Business
5.6.3 Pfizer Non-small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.6.4 Pfizer Non-small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Pfizer Recent Developments
5.7 Eli Lilly
5.7.1 Eli Lilly Profile
5.7.2 Eli Lilly Main Business
5.7.3 Eli Lilly Non-small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.7.4 Eli Lilly Non-small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Eli Lilly Recent Developments
5.8 Sanofi
5.8.1 Sanofi Profile
5.8.2 Sanofi Main Business
5.8.3 Sanofi Non-small Cell Lung Cancer Therapeutics Products, Services and Solutions
5.8.4 Sanofi Non-small Cell Lung Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Sanofi Recent Developments
6 North America
6.1 North America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Non-small Cell Lung Cancer Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Non-small Cell Lung Cancer Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Non-small Cell Lung Cancer Therapeutics Market Dynamics
11.1 Non-small Cell Lung Cancer Therapeutics Industry Trends
11.2 Non-small Cell Lung Cancer Therapeutics Market Drivers
11.3 Non-small Cell Lung Cancer Therapeutics Market Challenges
11.4 Non-small Cell Lung Cancer Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
